Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.

Journal of experimental & clinical cancer research : CR - 25 Jun 2018

Zhu Linlin, Zou Jiao, Zhao Yuanyin, Jiang Xiaomei, Wang Yang, Wang Xiangwei, Chen Bin

Abstract excerpt

BACKGROUND: ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the expression and role of ER-α36 in cisplatin resistance of breast cancer cells and elucidates its underlying mechanisms. METHODS: The expression of ER-α36 and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Estrogen Receptor alpha

Share to Estrogens

Share to Extracellular Signal-Regulated MAP Kinases

Share to Receptor, ErbB-2

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29940998
DOI: 10.1186/s13046-018-0798-z
PMCID: PMC6019204

Genes

EGFR
CCK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.PMID 29940998Read ↗

Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancerSemantic proximity Read ↗

The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancerSemantic proximity Read ↗

Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues.Semantic proximity Read ↗

Roles of estrogen receptor α in endometrial carcinoma (Review)Semantic proximity Read ↗

A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signalingSemantic proximity Read ↗

Endocrine resistance in breast cancer--An overview and update.Semantic proximity Read ↗

A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.Semantic proximity Read ↗

Estrogen Receptor Variant ER-α36 Facilitates Estrogen Signaling Via EGFR Signaling in GlioblastomaSemantic proximity Read ↗

Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.Semantic proximity Read ↗

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.Semantic proximity Read ↗

The G-protein-coupled estrogen receptor, a gene co-expressed with ERα in breast tumors, is regulated by estrogen-ERα signalling in ERα positive breast cancer cellsSemantic proximity Read ↗

Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.